What Oncolytic Viruses Are FDA Approved? 

Oncolytic viruses are a promising new treatment option for cancer patients, as they have the ability to selectively target and destroy cancer cells while leaving healthy cells unharmed. The FDA has approved several oncolytic viruses for use in cancer therapy, including talimogene laherparepvec (T-VEC) for the treatment of melanoma.
T-VEC is a genetically modified herpes simplex virus that works by infecting and replicating within cancer cells, causing them to burst and die. In addition to directly killing cancer cells, T-VEC also stimulates an immune response against the tumor, further enhancing its effectiveness.
Overall, oncolytic viruses represent a promising new frontier in cancer therapy, offering a targeted and potentially more effective treatment. With continued research and development in this field, it is likely that more oncolytic viruses will receive FDA approval in the future, providing hope for patients battling this devastating disease.